Entecavir
From Wikipedia, the free encyclopedia
 |
|
|
Entecavir
|
|
| Systematic (IUPAC) name | |
| 2-amino-9-[4-hydroxy-3-(hydroxymethyl)- 2-methylidene-cyclopentyl]-3H-purin-6-one |
|
| Identifiers | |
| CAS number | 142217-69-4 |
| ATC code | J05AF10 |
| PubChem | 153941 |
| DrugBank | APRD00948 |
| Chemical data | |
| Formula | C12H15N5O3 |
| Mol. weight | 277.279 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 13% |
| Metabolism | ? |
| Half life | 128–149 hours |
| Excretion | Renal 62–73% |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
C(US) |
| Legal status |
℞-only(US) |
| Routes | Oral |
Entecavir (INN) (IPA: [ɛnˈtɛkavir]) is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
